falsefalse

ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 1

Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC

, , ,

Dr. Pedro Barata, MD, MSc, provides an overview of advanced clear cell renal cell carcinoma (RCC), discussing its typical presentation, the role of systemic therapies, and summarizing the first-line treatment options available for this condition.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
    EP. 2: Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
    EP. 3: Dr Xu Reviews Data from the CLEAR Trial and Recent Analyses at ASCO 2024 - Lenvatinib + Pembrolizumab in Frontline Advanced RCC
    EP. 4: Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
    EP. 5: Exciting Data and Trials in Progress from ASCO 2024
    EP. 6: Ongoing RCC Clinical Trials that may Impact Practice
    EP. 7: Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
    EP. 8: Dr Voss Application of Updated KEYNOTE-564 Data
    EP. 9: Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
    EP. 10: World Health Organization (WHO) Classification Updates for Papillary RCC
    EP. 11: Additional Forward-Looking Data and Studies Beyond Frontline Therapy in RCC
    EP. 12: The Role of Chemotherapy in nccRCC Treatment
    EP. 13: Select Ongoing Trials for nccRCC and Impact on the Treatment Landscape
    EP. 14: Final Thoughts/Looking Forward
    1. Please give an introduction of advanced clear cell RCC, including typical disease presentation and the role of systemic therapies in treatment. 
      1. Please give a summary of the first-line treatment options for advanced clear cell RCC
      2. How do you approach treatment selection (IO+IO vs. IO+TKI, etc.) in the frontline setting?
    2. Are there any key patient characteristics that inform this decision?

    Related Content:

    ASCO 2024: Updates in the Treatment of Advanced Renal Cell CarcinomaClinicalOncLive Peer Exchange® Video Series
    Clinical Perspectives: 59yF with R/R CLL Experiencing BTKi Treatment-Related AE
    Expert Perspectives: Sequencing Strategies after Acalabrutinib + Venetoclax +/- Obinutuzumab as First-Line Therapy in CLL
    Expert Perspectives: Standardizing HER2 Testing in Gynecological Cancer
    x